Major inflection point.

What does it mean that the CMS decision to cover CAR-T cell therapy for all FDA-approved indications? For both Yescarta and Kymriah, that includes relapsed/refractory large B-cell lymphomas after two lines of therapy. Kymriah is also approved for refractory B-cell precursor ALL in patients under 25. | CMS 2019

Comments

  1. This. This is exactly why I decided to start blogging. It can be very isolating being home with babies, even if you get out and do stuff each day. It is so nice to read about another woman going through it too!
    friv jogos gratis
    friv 4 school games unblocked
    a10 Games for boys

    ReplyDelete

Post a Comment

Popular Posts